SEC Company Response from Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Nov 24, 2010
Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: Nov. 24, 2010 · CIK: 0001228627 · Accession: 0001140361-10-047167
AI Filing Summary & Sentiment
File numbers found in text: 001-34079
Referenced dates: October 15, 2010, September 17, 2010
Show Raw Text
CORRESP
1
filename1.htm
formcorresp.htm
2550 M Street NW
Washington DC 20037
(202) 457-6315
_____________
Facsimile (202) 457-6315
November 24, 2010
Hwan Kim
202-457-8025
HKim@pattonboggs.com
Ms. Keira Nakada
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Re: Rexahn Pharmaceuticals, Inc.
Form 10-K for the year ended December 31, 2009
Schedule 14A filed April 26, 2010
File No. 001-34079
Dear Ms. Nakada:
On behalf of Rexahn Pharmaceuticals, Inc. (the “Company”), we hereby request that the Staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) grant the Company an extension for filing its response to the Staff’s oral comments received on November 11, 2010 regarding Question 5 of the Staff’s letter to Dr. Chang Ahn dated September 17, 2010 and the Company’s response letter dated October 15, 2010. The Company expects to file its response to the Staff’s oral comments on or before December 3, 2010.
The Company thanks you for your consideration of the requested extension and is available to answer any questions you may have.
Respectfully submitted,
/s/Hwan Kim
Hwan Kim